Last reviewed · How we verify
CYT002-NicQb
At a glance
| Generic name | CYT002-NicQb |
|---|---|
| Sponsor | Cytos Biotechnology AG |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Improving the Efficacy of Anti-Nicotine Immunotherapy (PHASE2)
- Efficacy and Safety of Nicotine-Qbeta Vaccine in Smokers (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |